https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-10-19 / Cell Death Differ. 2008 Jan;15(1):58-69
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-10-19 / Cell Death Differ. 2008 Jan;15(1):58-692007-10-19 00:00:002019-02-15 08:44:36The ‚kiss of death‘ by dendritic cells to cancer cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-10-17 / Clin. Vaccine Immunol. 2008 Feb;15(2):284-92
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-10-17 / Clin. Vaccine Immunol. 2008 Feb;15(2):284-922007-10-17 00:00:002019-02-15 09:15:07Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-10-15 / Cancer 2007 Oct;110(8):1677-86
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-10-15 / Cancer 2007 Oct;110(8):1677-862007-10-15 00:00:002007-10-15 00:00:00Breast cancer vaccines: promise for the future or pipe dream?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-10-09 / Br. J. Cancer 2007 Nov;97(9):1251-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-10-09 / Br. J. Cancer 2007 Nov;97(9):1251-92007-10-09 00:00:002019-02-15 08:50:17Numerical and functional defects of blood dendritic cells in early- and late-stage breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-10-09 / Mol. Ther. 2008 Jan;16(1):210-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-10-09 / Mol. Ther. 2008 Jan;16(1):210-72007-10-09 00:00:002019-02-15 08:37:36Vaccination against hepatitis C virus with dendritic cells transduced with an adenovirus encoding NS3 protein
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-10-06 / BMC Cancer 2007 Oct;7:189
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-10-06 / BMC Cancer 2007 Oct;7:1892007-10-06 00:00:002019-02-15 08:35:03Docetaxel weekly regimen in conjunction with RF hyperthermia for pretreated locally advanced non-small cell lung cancer: a preliminary study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-10-04 / Gene Ther. 2007 Dec;14(23):1639-49
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-10-04 / Gene Ther. 2007 Dec;14(23):1639-492007-10-04 00:00:002020-06-23 09:33:03Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-10-03 / Clin. Immunol. 2007 Dec;125(3):257-67
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-10-03 / Clin. Immunol. 2007 Dec;125(3):257-672007-10-03 00:00:002019-02-15 09:16:54Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-10-01 / Br. J. Nutr. 2007 Oct;98 Suppl 1:S29-35
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-10-01 / Br. J. Nutr. 2007 Oct;98 Suppl 1:S29-352007-10-01 00:00:002007-10-01 00:00:00Selected vitamins and trace elements support immune function by strengthening epithelial barriers and cellular and humoral immune responses
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-10-01 / Melanoma Res. 2007 Oct;17(5):316-22
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-10-01 / Melanoma Res. 2007 Oct;17(5):316-222007-10-01 00:00:002019-02-15 09:19:38Dendritic cell immunotherapy for stage IV melanoma
